Lymphovascular Invasion in Non-Small-Cell Lung Cancer Implications for Staging and Adjuvant Therapy

被引:97
|
作者
Higgins, Kristin A. [1 ]
Chino, Junzo P. [2 ]
Ready, Neal [3 ]
D'Amico, Thomas A. [4 ]
Berry, Mark F. [4 ]
Sporn, Thomas [5 ]
Boyd, Jessamy [6 ]
Kelsey, Chris R. [2 ]
机构
[1] Emory Univ, Winship Canc Inst, Dept Radiat Oncol, Atlanta, GA 30322 USA
[2] Duke Univ, Med Ctr, Div Radiat Oncol, Durham, NC 27710 USA
[3] Duke Univ, Med Ctr, Dept Med, Div Med Oncol, Durham, NC 27710 USA
[4] Duke Univ, Med Ctr, Dept Surg, Div Cardiovasc & Thorac Surg, Durham, NC 27710 USA
[5] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA
[6] US Oncol, Natl Comprehens Canc Network, Dallas, TX USA
关键词
Lymphovascular invasion; Lung cancer; Local failure; VINORELBINE PLUS CISPLATIN; PELVIC RADIATION-THERAPY; LOCAL RECURRENCE; CARCINOMA; SURGERY; TRIAL;
D O I
10.1097/JTO.0b013e3182519a42
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Lymphovascular space invasion (LVI) is an established negative prognostic factor and an indication for postoperative radiation therapy in many malignancies. The purpose of this study was to evaluate LVI in patients with early-stage non-small-cell lung cancer, undergoing surgical resection. Methods: All patients who underwent initial surgery for pT1-3N0-2 non-small-cell lung cancer at Duke University Medical Center from 1995 to 2008 were identified. A multivariate ordinal regression was used to assess the relationship between LVI and pathologic hilar and/or mediastinal lymph node (LN) involvement. A multivariate Cox regression analysis was used to evaluate the relationship of LVI and other clinical and pathologic factors on local failure (LF), freedom from distant metastasis (FFDM), and overall survival (OS). Kaplan-Meier methods were used to generate estimates of LF, FFDM, and OS in patients with and without LVI. Results: One thousand five hundred and fifty-nine patients were identified. LVI was independently associated with the presence of regional LN involvement (p < 0.001) along with lobar (versus sublobar) resections (p < 0.001), and an open thoracotomy (versus video-assisted thoracoscopic surgery). LVI was not independently associated with LF on multivariate analysis (hazard ratio [HR] = 1.23, p = 0.25), but was associated with a lower FFDM (HR 1.52, p = 0.005) and OS (HR 1.26, p = 0.015). In addition, multivariate analysis showed that LVI was strongly associated with increased risk of developing distant metastases (HR = 1.75, p = 0.006) and death (HR = 1.53, p = 0.003) in adenocarcinomas but not in squamous carcinomas. Conclusions: LVI is associated with an increased risk of harboring regional LN involvement. LVI is also an adverse prognostic factor for the development of distant metastases and long-term survival.
引用
收藏
页码:1141 / 1147
页数:7
相关论文
共 50 条
  • [1] Lymphovascular Invasion in Non-small Cell Lung Cancer: Implications for Staging and Adjuvant Therapy
    Higgins, K. A.
    Chino, J. P.
    Yoo, D. S.
    Kelsey, C. R.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S573 - S573
  • [2] Adjuvant Therapy for Resected Non-Small-Cell Lung Cancer with Lymphovascular Invasion Response
    Rami-Porta, Ramon
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (01) : E9 - E10
  • [3] Lymphovascular Invasion in Non-Small-Cell Lung Cancer
    Salvati, Franco
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (01) : E8 - E9
  • [4] Prognostic Effect of Lymphovascular Invasion on TNM Staging in Stage I Non-Small-cell Lung Cancer
    Noma, Daisuke
    Inamura, Kentaro
    Matsuura, Yosuke
    Hirata, Yoshifumi
    Nakajima, Takuya
    Yamazaki, Hirotsugu
    Hirai, Yoshimitsu
    Ichinose, Junji
    Nakao, Masayuki
    Ninomiya, Hironori
    Mun, Mingyon
    Nakagawa, Ken
    Masuda, Munetaka
    Ishikawa, Yuichi
    Okumura, Sakae
    [J]. CLINICAL LUNG CANCER, 2018, 19 (01) : E109 - E122
  • [5] Adjuvant therapy for non-small-cell lung cancer
    Kalemkerian, Gregory P.
    [J]. LANCET, 2010, 375 (9722): : 1230 - 1231
  • [6] Adjuvant therapy of resected non-small-cell lung cancer
    Keller, SM
    [J]. CURRENT OPINION IN ONCOLOGY, 2000, 12 (02) : 149 - 155
  • [7] Pembrolizumab as adjuvant therapy in non-small-cell lung cancer
    Uprety, Dipesh
    [J]. LANCET ONCOLOGY, 2022, 23 (12): : E527 - E527
  • [8] ADJUVANT THERAPY OF NON-SMALL-CELL LUNG-CANCER
    HOLMES, EC
    [J]. HEMATOLOGICAL ONCOLOGY, 1992, 10 (01) : 21 - 24
  • [9] Staging of Non-Small-Cell Lung Cancer
    Akhurst, Tim
    [J]. PET CLINICS, 2018, 13 (01) : 1 - +
  • [10] NEOADJUVANT AND ADJUVANT THERAPY OF NON-SMALL-CELL LUNG-CANCER
    ROSE, LJ
    [J]. SEMINARS IN ONCOLOGY, 1991, 18 (06) : 536 - 542